Tucatinib, palbociclib, and letrozole in HR+/HER2+metastatic breast cancer: Report of phase IB safety cohort.

被引：11
|
作者：
Shagisultanova, Elena
Chalasani, Pavani
Brown-Glaberman, Ursa Abigail
Gradishar, William John
Brenner, Andrew Jacob
Stopeck, Alison
Gao, Dexiang
McSpadden, Tessa
Kabos, Peter
Borges, Virginia F.
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
[3] UNM, Ctr Canc, Albuquerque, NM USA
[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[5] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[6] Stony Brook Canc Ctr, Stony Brook, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.1029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1029
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+Breast Cancer
    Shagisultanova, Elena
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    Brenner, Andrew J.
    Stopeck, Alison
    Parris, Hannah
    Gao, Dexiang
    McSpadden, Tessa
    Mayordomo, Jose
    Diamond, Jennifer R.
    Kabos, Peter
    Borges, Virginia F.
    CLINICAL CANCER RESEARCH, 2023, 29 (24) : 5021 - 5030
  • [2] Intracranial efficacy of tucatinib, palbociclib and letrozole combination in patients with HR+/HER2+breast cancer and brain metastases
    Shagisultanova, Elena
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    Brenner, Andrew
    Stopeck, Alison
    Mayordomo, Jose
    Diamond, Jennifer
    Kabos, Peter
    Borges, Virginia F.
    CANCER RESEARCH, 2022, 82 (04)
  • [3] Evolving perspectives on the treatment of HR+/HER2+metastatic breast cancer
    Pegram, Mark
    Pietras, Richard
    Dang, Chau T.
    Murthy, Rashmi
    Bachelot, Thomas
    Janni, Wolfgang
    Sharma, Priyanka
    Hamilton, Erika
    Saura, Cristina
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [4] Treatment patterns and their impact on the outcome of patients with HR+/HER2+metastatic breast cancer in a large real-world cohort.
    Carausu, Marcela
    Carton, Matthieu
    Dieras, Veronique C.
    Petit, Thierry
    Lahaye, Severine Guiu
    Veyret, Corinne
    Goncalves, Anthony
    Augereau, Paule
    Ferrero, Jean-Marc
    Levy, Christelle
    Ung, Mony
    Desmoulins, Isabelle
    Debled, Marc
    Bachelot, Thomas
    Eymard, Jean-Christophe
    Pistilli, Barbara
    Frenel, Jean-Sebastien
    Chevrot, Michael
    Mailliez, Audrey
    Cabel, Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Interim safety and efficacy analysis of phase IB/II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer
    Shagisultanova, Elena
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    Brenner, Andrew J.
    Stopeck, Alison
    Mayordomo, Jose
    Diamond, Jennifer R.
    Kabos, Peter
    Borges, Virginia F.
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
    Ban, Marija
    Mise, Branka Petric
    Majic, Ana
    Drazic, Ivanka
    Vrdoljak, Eduard
    FUTURE ONCOLOGY, 2018, 14 (06) : 537 - 544
  • [7] Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer
    Shagisultanova, Elena
    Diamond, Jennifer
    Stopeck, Alison
    Pusztai, Lajos
    O'Regan, Ruth
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    McSpadden, Tessa
    Borakove, Michelle
    Shedin, Troy
    Kabos, Peter
    Borges, Virginia
    CANCER RESEARCH, 2018, 78 (04)
  • [8] COST-EFFECTIVENESS OF PALBOCICLIB PLUS LETROZOLE IN THE TREATMENT OF HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN ECUADOR
    Cabezas, M.
    Freire, V
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [9] Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2-advanced breast cancer: A phase Ib study.
    Zhang, Qingyuan
    Zhang, Pin
    Yan, Min
    Yan, Xi
    Wang, Xian
    Gu, Yuanting
    Qu, Xiujuan
    Li, Shaorong
    Xu, Guoying
    Yang, Wenhui
    Zhu, Xiaoyu
    Zhang, Xiaojing
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] HR+/HER2 Breast Cancer Palbociclib: Effective, simple, and safe
    Sonnet, Miriam
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (06)
12345